Patient Condition
Advanced intrahepatic cholangiocarcinoma, IDH1R132C mutation positive (confirmed by Guardant 360NGS test), multiple intrahepatic metastases, CA19 -9 560U/mL, progressed after 4 cycles of first-line Gem/Cis chemotherapy.
Treatment Timeline
| Phase | Details | Date |
|---|
| Progress after frontline chemotherapy | | |
| IDH1 inhibitor treatment | | |
| efficacy assessments | | |
| ongoing treatment for | | |
Treatment Outcome
| before | Advanced intrahepatic cholangiocarcinoma positive for IDH1 mutation, progressed after first-line chemotherapy, multiple liver metastases, CA19 -9 560U/mL |
|---|
| after | 12 cycles of Ivosidenib combined with Gemcitabine reduced liver metastases by 30%, and CA19 -9 to 280U/mL |
|---|
| highlight | Second-line treatment with Ivosidenib combined with Gemcitabine for IDH1 mutation-positive cholangiocarcinoma reduced liver metastases by 30% |
|---|